![]() |
Program
†
Research Areas
Partners
Education
Members
Facilities |
|
Tuesday, February 13, 2007 |
|
|
Optical Molecular Imaging - An Industrial Perspective |
|
|
Paul O. McLaughlin |
|
|
In the past decade, the identification of unique molecular biomarkers of disease has led to the development of new nano-technologies for early detection and treatment. Molecular imaging is the spatially localized and/or temporally resolved sensing of molecular and cellular processes in-vivo. Noninvasive imaging of molecular markers of cancer and other diseases requires target-specific imaging probes as well as imaging systems that are sensitive, cost-effective, rapid, and can be used in real time. Optical molecular imaging is a relatively new modality. Near-infrared fluorescence (NIRF)-enhanced nanoparticles have been synthesized and tested as optical contrast agents. Optical molecular imaging offers several advantages over conventional imaging modalities in that it is extremely sensitive, inexpensive, robust, and involves no harmful radiation. The experimental protocol and results of recent in-vivo testing of our NIRF nanoparticles will be reported. |
|
|
Dr. Paul McLaughlin joined Eastman Kodak Company in 1995 as a Research Scientist in the Optical Manufacturing Process Development (OMPD) group. In 1998, he was promoted to Unit Director of OMPD and, in 2002, he was appointed Director of the
From 1983 to 1986, Dr. McLaughlin was a staff researcher at Nippon Sheet Glass Company, Central Research Laboratory,
Dr. McLaughlin received a BS Magna Cum Laude in physics from
|
Home
Program
Research Areas
Partners
Education
Members
Facilities
|